Embecta Corp Q4 2025 Earnings Call Highlights: Strategic Advances Amid Revenue Decline

martes, 25 de noviembre de 2025, 2:07 pm ET1 min de lectura
EMBC--

Embecta Corp's Q4 2025 earnings call highlights strategic advances despite revenue challenges. The company completed its ERP implementation and operationalized a new distribution network in Latin America and India. Embecta also advanced its GLP-1 strategy with over 30 pharmaceutical partners and generated $182 million in free cash flow, exceeding its debt target. However, revenue declined 7.7% YoY due to unfavorable comparisons and milestone payments. The company anticipates a decline in adjusted operating margin for fiscal year 2026 due to increased cannula costs and higher R&D expenses.

Embecta Corp Q4 2025 Earnings Call Highlights: Strategic Advances Amid Revenue Decline

Comentarios



Add a public comment...
Sin comentarios

Aún no hay comentarios